Thomas G. Martin 3rd, MD

Thomas G. Martin 3rd, MD, is a clinical professor of medicine; associate chief of the Division of Hematology and Oncology; director of the Hematology, Blood, and Marrow Transplantation and Cellular Therapy Program; and co-leader of the Cancer Immunology and Immunotherapy Program at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco.

Dr Martin has authored numerous articles in hematologic malignancies and has been a thought leader and an invited speaker at national and international meetings. He has been actively involved in clinical research and has been principal investigator for more than 50 clinical trials. Dr Martin’s main research interests are the early-phase development and evaluation of novel therapeutics for multiple myeloma. He was actively involved in the clinical development of the novel anti-CD38 monoclonal antibody isatuximab, and he initiated the first phase 1 trial combining carfilzomib with isatuximab. Moreover, he recently received a $4.6 million grant to help develop a homegrown BCMA CAR T-cell therapeutic at the University of California, San Francisco, and this nonviral asset is now in a phase 1 trial. Dr Martin continues to be active in immunotherapy trials, including bispecific and CAR T-cell trials.